References
- Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203.
- World Health Organization. Obesity and overweight. 2021 [cited 2022 Apr 14]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
- Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020;360:1–8.
- Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875–E891.
- Garvey WT. New horizons. A new paradigm for treating to target with second-generation obesity medications. J Clin Endocrinol Metab. 2022;107(4):e1339–e1347.
- Jensen MD, Ryan DH, Apovian CM, et al. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–S138. 2013.
- Semlitsch T, Stigler FL, Jeitler K, et al. Management of overweight and obesity in primary care-a systematic overview of international evidence-based guidelines. Obes Rev. 2019;20(9):1218–1230.
- Campbell-Scherer D, Walji S, Kemp A, et al. Canadian adult obesity clinical practice guidelines: primary care and primary healthcare in obesity management. 2022 [cited 2022 Mar 16]. Available from: https://obesitycanada.ca/guidelines/primarycare
- Kirk SFL, Ramos Salas X, Alberga AS, et al. Canadian adult obesity clinical practice guidelines: reducing weight bias in obesity management, practice and policy. 2020 [cited 2022 Mar 16]. Available from: https://obesitycanada.ca/guidelines/weightbias.
- Gomez G, Stanford FC. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes (Lond). 2018;42(3):495–500.
- Petrin C, Kahan S, Turner M, et al. Current attitudes and practices of obesity counselling by health care providers. Obes Res Clin Pract. 2017;11(3):352–359.
- Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med. 2020;26(4):485–497.
- Puhl R, Suh Y. Health consequences of weight stigma: implications for obesity prevention and treatment. Curr Obes Rep. 2015;4(2):182–190.
- Theilade S, Christensen MB, Vilsbøll T, et al. An overview of obesity mechanisms in humans: endocrine regulation of food intake, eating behaviour and common determinants of body weight. Diabetes Obes Metab. 2021;23(Suppl 1):17–35.
- Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111–2120.
- Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020;28(3):529–536.
- Berthoud H-R, Morrison CD, Münzberg H. The obesity epidemic in the face of homeostatic body weight regulation: what went wrong and how can it be fixed? Physiol Behav. 2020;222:112959.
- Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–837.
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157.
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130.
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.
- Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429.
- Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–536.
- Sisley S, Gutierrez-Aguilar R, Scott M, et al. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J Clin Invest. 2014;124(6):2456–2463.
- Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754–762.
- US Food and Drug Administration. Ozempic® – Prescribing Information. 2021 [cited 2022 Apr 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s012lbl.pdf
- US Food and Drug Administration. Victoza® – Prescribing Information. 2017 [cited 2022 Oct 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf
- US Food and Drug Administration. SAXENDA (liraglutide) injection for subcutaneous use. 2018 [cited 2022 Mar 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206321s007lbl.pdf?msclkid=48a40878a55211ec92c79af950e10e24.
- Novo Nordisk. Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management. 2014 [cited 2022 Mar 16]. Available from: https://www.novonordisk-us.com/content/nncorp/us/en_us/media/news-archive/news-details.html?id=36775
- Novo Nordisk. United States first country to launch Saxenda®. 2015 [cited 2022 Mar 16]. Available from: https://www.worldpharmanews.com/novonordisk/3070-united-states-first-country-to-launch-saxendar#:~:text=United%20States%20first%20country%20to%20launch%20Saxenda%C2%AE%20Novo,management%2C%20approved%20in%20the%20US%2C%20EU%20and%20Canada.
- US Food and Drug Administration. WEGOVY (semaglutide) injection for subcutaneous use. 2021 [cited 2022 Apr 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf?msclkid=97a9aae0a55211ecb2cd7cf8ff0cb54c
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989.
- Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050–1061.
- Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251.
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984.
- Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425.
- Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083–2091.
- Ul-Haq Z, Mackay DF, Fenwick E, et al. Meta-analysis of the association between body mass index and health-related quality of life among adults, assessed by the SF-36. Obesity (Silver Spring). 2013;21(3):E322–E327.
- Nygaard CC, Schreiner L, Morsch TP, et al. Urinary incontinence and quality of life in female patients with obesity. Rev Bras Ginecol Obstet. 2018;40(9):534–539.
- Sutin AR, Stephan Y, Terracciano A. Weight discrimination and risk of mortality. Psychol Sci. 2015;26(11):1803–1811.
- Sattler KM, Deane FP, Tapsell L, et al. Gender differences in the relationship of weight-based stigmatisation with motivation to exercise and physical activity in overweight individuals. Health Psychol Open. 2018;5(1):2055102918759691.
- Gudzune KA, Bennett WL, Cooper LA, et al. Perceived judgment about weight can negatively influence weight loss: a cross-sectional study of overweight and obese patients. Prev Med. 2014;62:103–107.
- Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14–19.